Johnson Andrea H, Brennan Jane C, Simpson Shawn S, Turcotte Justin J, King Paul J
Department of Orthopedics, Luminis Health Anne Arundel Medical Center, Annapolis, MD, USA.
Arthroplast Today. 2025 Apr 26;33:101690. doi: 10.1016/j.artd.2025.101690. eCollection 2025 Jun.
Medications used for pharmacologic venous thromboembolism prophylaxis are associated with postoperative complications including bleeding, wound complications, and infection. These same medications are used for chronic anticoagulation, and little research has been done on total knee arthroplasty (TKA) complications associated with these medications, particularly manipulation under anesthesia (MUA) and revision TKA. The purpose of this study is to evaluate the rate of MUA and other early postoperative complications in patients undergoing TKA with a preoperative history of chronic anticoagulation.
The TriNetX database was retrospectively queried for all patients undergoing TKA with perioperative tranexamic acid. Patients were divided into cohorts by whether or not they had a history of chronic anticoagulant use and had an anticoagulant medication prescribed within 6 months of surgery. The cohorts were propensity score matched on demographic and comorbidity data; 7367 patients remained in each cohort after matching.
Patients with chronic anticoagulant use were 1.72 times more likely to undergo an MUA (odds ratio [OR]: 1.718, 95% confidence intervals [CI]: 1.403-2.104; < .001), 1.32 times more likely to have a revision TKA (OR: 1.324, 95% CI: 1.006-1.742; = .044), and were 1.53 times more likely to have wound disruption (OR: 1.530, 95% CI: 1.214-1.927; < .001) within the 1-year postoperative period.
Patients undergoing TKA while on chronic anticoagulation have worse outcomes within 1 year postoperatively than patients not on chronic anticoagulation. Further studies are needed to validate these findings and to identify sources of the increased risk of complications in this population, as well as identify factors that may mitigate this risk.
用于药物性静脉血栓栓塞预防的药物与术后并发症相关,包括出血、伤口并发症和感染。这些药物也用于慢性抗凝治疗,而关于这些药物与全膝关节置换术(TKA)并发症,特别是麻醉下手法操作(MUA)和TKA翻修术相关的研究较少。本研究的目的是评估有慢性抗凝治疗病史的患者在接受TKA时MUA的发生率及其他早期术后并发症。
对TriNetX数据库进行回顾性查询,以获取所有接受TKA并围手术期使用氨甲环酸的患者。根据患者是否有慢性抗凝药物使用史以及在手术6个月内是否开具了抗凝药物处方,将患者分为不同队列。对各队列的人口统计学和合并症数据进行倾向评分匹配;匹配后每个队列各有7367例患者。
有慢性抗凝药物使用史的患者接受MUA的可能性高1.72倍(比值比[OR]:1.718,95%置信区间[CI]:1.403 - 2.104;P <.001),进行TKA翻修术的可能性高1.32倍(OR:1.324,95%CI:1.006 - 1.742;P =.044),并且在术后1年内伤口裂开的可能性高1.53倍(OR:1.530,95%CI:1.214 - 1.927;P <.001)。
接受TKA时正在进行慢性抗凝治疗的患者术后1年内的结局比未进行慢性抗凝治疗的患者更差。需要进一步研究来验证这些发现,并确定该人群并发症风险增加的来源,以及识别可能减轻这种风险的因素。